4//SEC Filing
Parsey Merdad 4
Accession 0001127602-24-026735
CIK 0000882095other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 4:32 PM ET
Size
9.9 KB
Accession
0001127602-24-026735
Insider Transaction Report
Form 4
Parsey Merdad
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-11-06$57.92/sh+25,000$1,448,000→ 125,189 total - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2024-11-06−25,000→ 121,670 totalExercise: $57.92Exp: 2032-03-10→ Common Stock (25,000 underlying) - Sale
Common Stock
2024-11-06$91.50/sh−5,000$457,500→ 99,599 total - Sale
Common Stock
2024-11-06$91.50/sh−20,590$1,883,985→ 104,599 total
Footnotes (2)
- [F1]The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023.
- [F2]The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Documents
Issuer
GILEAD SCIENCES, INC.
CIK 0000882095
Entity typeother
Related Parties
1- filerCIK 0001792150
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 4:32 PM ET
- Size
- 9.9 KB